Midostaurin has demonstrated activity as a single agent [6], has induced complete remissions in combination with chemotherapy in patients with AML [7], and is currently under evaluation in a phase III registration trial in patients with newly diagnosed FLT3-mutant AML at a dose of 50 mg twice daily in combination with standard chemotherapy [8]. The gene discussed is FLT3; the disease is acute myeloid leukemia.